ADMA
ADMA Biologics, Inc. [ADMA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ADMA Stock Summary
Top 10 Correlated ETFs
ADMA
Top 10 Correlated Stocks
ADMA
In the News
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Why Shares of ADMA Biologics Are Climbing Thursday
ADMA grew revenue and trimmed its losses compared to the same quarter a year ago. The company increased revenue guidance for 2023, 2024, and 2025.
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.
New Strong Buy Stocks for July 7th
ADMA, APOG, KIND, JBL and OII have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2023.
GSK Announces Extension of FDA Review for Rare Blood Therapy
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
ADMA Biologics: An Emerging Growth Play
Today, we take a deeper look at ADMA Biologics, Inc., whose stock has doubled over the past year thanks to robust sales growth. The company continues to expand its plasma collection network, is delivering impressive growth and is pursuing margin enhancing initiatives. An investment analysis follows in the paragraphs below.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.
ADMA Financial details
ADMA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.38 | 0.54 | 0.49 | 0.58 | 0.78 | |
| Net income per share | -1.45 | -1.05 | -1.02 | -0.61 | -0.43 | |
| Operating cash flow per share | -1.39 | -1.4 | -1.18 | -0.81 | -0.3 | |
| Free cash flow per share | -1.43 | -1.47 | -1.33 | -0.9 | -0.37 | |
| Cash per share | 0.5 | 0.49 | 0.65 | 0.37 | 0.44 | |
| Book value per share | 0.44 | 0.48 | 1.02 | 1.01 | 0.77 | |
| Tangible book value per share | 0.27 | 0.36 | 0.96 | 0.97 | 0.75 | |
| Share holders equity per share | 0.44 | 0.48 | 1.02 | 1.01 | 0.77 | |
| Interest debt per share | 1.1 | 1.72 | 1.27 | 0.83 | 0.88 | |
| Market cap | 108M | 217.39M | 167.98M | 196.81M | 767.75M | |
| Enterprise value | 129.47M | 275.37M | 209.73M | 248.64M | 835.68M | |
| P/E ratio | -1.64 | -3.81 | -1.92 | -2.33 | -9.01 | |
| Price to sales ratio | 6.36 | 7.41 | 3.98 | 2.43 | 4.98 | |
| POCF ratio | -1.72 | -2.85 | -1.65 | -1.75 | -12.9 | |
| PFCF ratio | -1.67 | -2.72 | -1.46 | -1.56 | -10.46 | |
| P/B Ratio | 5.46 | 8.3 | 1.9 | 1.39 | 5.05 | |
| PTB ratio | 5.46 | 8.3 | 1.9 | 1.39 | 5.05 | |
| EV to sales | 7.62 | 9.38 | 4.97 | 3.07 | 5.42 | |
| Enterprise value over EBITDA | -2.28 | -6.88 | -3.27 | -4.3 | -21.3 | |
| EV to operating cash flow | -2.07 | -3.61 | -2.06 | -2.21 | -14.04 | |
| EV to free cash flow | -2 | -3.44 | -1.83 | -1.98 | -11.38 | |
| Earnings yield | -0.61 | -0.26 | -0.52 | -0.43 | -0.11 | |
| Free cash flow yield | -0.6 | -0.37 | -0.68 | -0.64 | -0.1 | |
| Debt to equity | 2.24 | 3.23 | 1.11 | 0.73 | 1.02 | |
| Debt to assets | 0.5 | 0.67 | 0.47 | 0.37 | 0.44 | |
| Net debt to EBITDA | -0.38 | -1.45 | -0.65 | -0.9 | -1.73 | |
| Current ratio | 4.63 | 6.12 | 7.71 | 6.87 | 6.89 | |
| Interest coverage | -10.92 | -4.61 | -5.42 | -4.47 | -2.04 | |
| Income quality | 0.95 | 1.58 | 1.35 | 1.57 | 0.9 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.32 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.23 | 0.08 | 0.14 | 0.05 | 0.02 | |
| Intangibles to total assets | 0.08 | 0.05 | 0.03 | 0.02 | 0.01 | |
| Capex to operating cash flow | 0.03 | 0.05 | 0.12 | 0.12 | 0.23 | |
| Capex to revenue | -0.12 | -0.13 | -0.3 | -0.17 | -0.09 | |
| Capex to depreciation | -0.61 | -1.17 | -3.23 | -2.46 | -1.96 | |
| Stock based compensation to revenue | 0.13 | 0.09 | 0.07 | 0.04 | 0.03 | |
| Graham number | 3.78 | 3.37 | 4.84 | 3.71 | 2.73 | |
| ROIC | -1.02 | -0.44 | -0.39 | -0.27 | -0.16 | |
| Return on tangible assets | -0.81 | -0.47 | -0.43 | -0.31 | -0.25 | |
| Graham Net | -0.8 | -0.83 | -0.15 | 0 | -0.08 | |
| Working capital | 34.9M | 71.79M | 133.79M | 178.35M | 231.13M | |
| Tangible asset value | 12.24M | 19.5M | 82.28M | 135.91M | 147.43M | |
| Net current asset value | -24.58M | -15.08M | 34.32M | 73.65M | 73.91M | |
| Invested capital | 2.24 | 3.23 | 1.11 | 0.73 | 1.02 | |
| Average receivables | 2.64M | 2.43M | 8.35M | 20.91M | 22.04M | |
| Average payables | 5.91M | 7.54M | 10.12M | 11.75M | 12.83M | |
| Average inventory | 15.62M | 35.84M | 67.3M | 103.13M | 144M | |
| Days sales outstanding | 29.92 | 43.15 | 114.44 | 128.86 | 36.73 | |
| Days payables outstanding | 51.04 | 84.77 | 65.95 | 56.87 | 40.64 | |
| Days of inventory on hand | 161.04 | 490.29 | 485.56 | 570.7 | 501.6 | |
| Receivables turnover | 12.2 | 8.46 | 3.19 | 2.83 | 9.94 | |
| Payables turnover | 7.15 | 4.31 | 5.53 | 6.42 | 8.98 | |
| Inventory turnover | 2.27 | 0.74 | 0.75 | 0.64 | 0.73 | |
| ROE | -3.33 | -2.18 | -0.99 | -0.6 | -0.56 | |
| Capex per share | -0.05 | -0.07 | -0.15 | -0.1 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.17 | 0.21 | 0.25 | 0.26 | 0.27 | |
| Net income per share | -0.09 | -0.1 | -0.13 | -0.06 | -0.03 | |
| Operating cash flow per share | -0.07 | -0.07 | -0.04 | -0.07 | -0.03 | |
| Free cash flow per share | -0.09 | -0.08 | -0.05 | -0.08 | -0.03 | |
| Cash per share | 0.27 | 0.18 | 0.43 | 0.31 | 0.28 | |
| Book value per share | 0.58 | 0.51 | 0.75 | 0.66 | 0.66 | |
| Tangible book value per share | 0.56 | 0.49 | 0.73 | 0.64 | 0.64 | |
| Share holders equity per share | 0.58 | 0.51 | 0.75 | 0.66 | 0.66 | |
| Interest debt per share | 0.79 | 0.81 | 0.79 | 0.73 | 0.71 | |
| Market cap | 388.78M | 477.21M | 786.98M | 734.56M | 821.7M | |
| Enterprise value | 487.63M | 595.03M | 854.9M | 821.08M | 910.7M | |
| P/E ratio | -5.3 | -5.82 | -7.59 | -14.39 | -32.25 | |
| Price to sales ratio | 11.47 | 11.61 | 15.75 | 12.91 | 13.67 | |
| POCF ratio | -30.3 | -35.92 | -106.65 | -49.89 | -135.62 | |
| PFCF ratio | -23.18 | -28.64 | -70.72 | -44.07 | -118.55 | |
| P/B Ratio | 3.4 | 4.75 | 5.18 | 5.04 | 5.6 | |
| PTB ratio | 3.4 | 4.75 | 5.18 | 5.04 | 5.6 | |
| EV to sales | 14.38 | 14.48 | 17.1 | 14.43 | 15.15 | |
| Enterprise value over EBITDA | -65.3 | -79.79 | -135.36 | -1.66K | 449.51 | |
| EV to operating cash flow | -38 | -44.79 | -115.85 | -55.77 | -150.31 | |
| EV to free cash flow | -29.08 | -35.7 | -76.83 | -49.26 | -131.39 | |
| Earnings yield | -0.05 | -0.04 | -0.03 | -0.02 | -0.01 | |
| Free cash flow yield | -0.04 | -0.03 | -0.01 | -0.02 | -0.01 | |
| Debt to equity | 1.32 | 1.52 | 1.02 | 1.07 | 1.03 | |
| Debt to assets | 0.51 | 0.51 | 0.44 | 0.46 | 0.44 | |
| Net debt to EBITDA | -13.24 | -15.8 | -10.75 | -174.97 | 43.93 | |
| Current ratio | 7.94 | 5.04 | 6.89 | 7.19 | 6.35 | |
| Interest coverage | -2.01 | -1.67 | -1.06 | -0.13 | -0.08 | |
| Income quality | 0.93 | 0.89 | 0.6 | 2.17 | 0.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.31 | 0.25 | 0.51 | 0.13 | 0.14 | |
| Capex to revenue | -0.12 | -0.08 | -0.07 | -0.03 | -0.01 | |
| Capex to depreciation | -2.29 | -1.82 | -1.94 | -0.96 | -0.42 | |
| Stock based compensation to revenue | 0.04 | 0.03 | 0.02 | 0.02 | 0.03 | |
| Graham number | 1.11 | 1.1 | 1.47 | 0.92 | 0.65 | |
| ROIC | -0.04 | -0.05 | -0.04 | 0 | 0 | |
| Return on tangible assets | -0.06 | -0.07 | -0.08 | -0.04 | -0.02 | |
| Graham Net | -0.22 | -0.35 | -0.08 | -0.11 | -0.11 | |
| Working capital | 194.7M | 179.65M | 231.13M | 227.36M | 224.29M | |
| Tangible asset value | 109.5M | 95.66M | 147.43M | 141.29M | 142.58M | |
| Net current asset value | 40.24M | 23.92M | 73.91M | 68.95M | 69.98M | |
| Invested capital | 1.32 | 1.52 | 1.02 | 1.07 | 1.03 | |
| Average receivables | 22.26M | 19.89M | 18.2M | 21.01M | 31.63M | |
| Average payables | 12.75M | 18.29M | 19.21M | 13.09M | 12.52M | |
| Average inventory | 142.61M | 154.49M | 163.1M | 163.63M | 162.88M | |
| Days sales outstanding | 50.13 | 45.78 | 27.92 | 41.93 | 54.98 | |
| Days payables outstanding | 39.22 | 72.15 | 33.25 | 28.86 | 25.04 | |
| Days of inventory on hand | 503.02 | 466.45 | 410.43 | 365.31 | 335.23 | |
| Receivables turnover | 1.8 | 1.97 | 3.22 | 2.15 | 1.64 | |
| Payables turnover | 2.3 | 1.25 | 2.71 | 3.12 | 3.59 | |
| Inventory turnover | 0.18 | 0.19 | 0.22 | 0.25 | 0.27 | |
| ROE | -0.16 | -0.2 | -0.17 | -0.09 | -0.04 | |
| Capex per share | -0.02 | -0.02 | -0.02 | -0.01 | 0 |
ADMA Frequently Asked Questions
What is ADMA Biologics, Inc. stock symbol ?
ADMA Biologics, Inc. is a US stock , located in Ramsey of Nj and trading under the symbol ADMA
Is ADMA Biologics, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $4.83. The lowest prediction is $4 and the highest is $6
What is ADMA stock prediction ?
What is ADMA Biologics, Inc. stock quote today ?
ADMA Biologics, Inc. stock price is $3.56 today.
Is ADMA Biologics, Inc. stock public?
Yes, ADMA Biologics, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.17M
- Market Capitalization 789.42M
- Employee 617
- CEO Mr. Adam S. Grossman
- Headquarters Ramsey,NJ,US
- IPO Date 2013-10-17
-
Website
https://www.admabiologics.com 
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
